Clinical trial · Interventional
Ultrasound and Photoacoustic Imaging for Cervical Cancer
Pilot Study of Ultrasound and Photoacoustic Imaging for Assessing Treatment Response of Cervical Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual
Summary
Brief summary (as posted)
The investigators have developed co-registered transvaginal photoacoustic and ultrasound (US) imaging techniques that allow them to visualize ovarian tumor structure and functional changes simultaneously, which may potentially reveal early tumor angiogenesis development or residual tumors after systemic treatment that is not available by US alone. The ability to detect early angiogenesis changes, as well as tumor morphology changes using a non-invasive imaging modality will greatly enhance the care for patients. The investigators plan to explore these techniques in monitoring cervical cancer treatment response and conduct pilot feasibility studies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the Cervix | Malignant Cervical Neoplasm | ALIAS | 0.90 |
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transvaginal probe using photoacoustic and ultrasound imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Transvaginal probe (Photoacoustic + ultrasound imaging)
- description
- * A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images * This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points
- interventionNames
- Device: Transvaginal probe using photoacoustic and ultrasound imaging
Primary outcomes (1)
- measure
- Number of participants who complete the imaging protocol
- timeFrame
- Approximately 18 weeks
Secondary outcomes (2)
- measure
- Reduction rate of tumor angiogenesis
- timeFrame
- 3 months after completion of standard of care treatment (approximately 18 weeks)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
* Diagnosis of cervical cancer of any stage that will be treated with radiation therapy and concurrent chemotherapy. * At least 18 years of age. * Not pregnant and/or breastfeeding. * Able to understand and willing to sign an IRB-approved written informed consent document.
References
Publications (0)
Data not yet available